DURECT announces amendment to accelerate ongoing phase 2a trial of DUR-928 in AH
DURECT announced it has amended its ongoing Phase 2a clinical trial of intravenously administered DUR-928 in patients with alcoholic hepatitis (AH) to accelerate the initiation of dosing of severe AH patents. The Company recently completed dosing for the low-dose 30 mg cohort of Part A. November 19, 2018